TPCA-1
Code | Size | Price |
---|
TAR-T3049-2mg | 2mg | £101.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T3049-5mg | 5mg | £119.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T3049-10mg | 10mg | £148.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T3049-25mg | 25mg | £211.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T3049-50mg | 50mg | £302.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T3049-100mg | 100mg | £429.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
TPCA-1 is an effective and specific IKK-2 inhibitor (IC50: 17.9 nM); shows >22-fold selectivity over IKK-1 and >550-fold selectivity over others kinases and enzymes.
CAS:
507475-17-4
Formula:
C12H10FN3O2S
Molecular Weight:
279.29
Pathway:
Stem Cells; JAK/STAT signaling; NF-κb; Apoptosis
Purity:
0.9929
SMILES:
NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1
Target:
Apoptosis; IκB/IKK; STAT
References
1. Podolin PL, et al, J Pharmacol Exp Ther, 2005, 312(1), 373-381.
2. Du Z, et al, J Interferon Cytokine Res, 2012, 32(8), 368-377.
3. Luebke T, Schwarz L, Beer Y Y, et al. c-FLIP and CD95 signaling are essential for survival of renal cell carcinoma[J]. Cell death & disease. 2019 May 16;10(6):384.